BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
Phase 2
Completed
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 330
- Registration Number
- NCT00245388
- Locations
- 🇨🇦
Local Institution, Ottawa, Ontario, Canada
A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1159
- Registration Number
- NCT00240370
- Locations
- 🇵🇷
Local Institution, Ponce, Puerto Rico
Dose Ranging Study With LT, Monotherapy, PPAR
Phase 2
Completed
- Conditions
- Diabetes Mellitus II
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1260
- Registration Number
- NCT00240383
- Locations
- 🇬🇧
Local Institution, Glasgow, United Kingdom
MAD Refractory: Solid Tumor QD w/o Break
Phase 1
Completed
- Conditions
- HER2 or EGFR Expressing Advanced Solid Malignancies
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00207012
- Locations
- 🇪🇸
Local Institution, Barcelona, Spain
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
Phase 1
Terminated
- Conditions
- Tumors
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00207025
- Locations
- 🇧🇪
Local Institution, Brussels, Belgium
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT00207051
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
Phase 4
Completed
- Conditions
- AIDS
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT00207168
Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)
Phase 4
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 252
- Registration Number
- NCT00207142
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT00207103
- Locations
- 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸University Of Wisconsin Comprehensive Center, Madison, Wisconsin, United States
🇬🇧Local Institution, Manchester, Greater Manchester, United Kingdom
Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
Phase 2
Completed
- Conditions
- Staphylococcus Aureus
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00198289
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath